Brokerages Set Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Price Target at $195.08

Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) have been given an average rating of “Moderate Buy” by the thirteen brokerages that are presently covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $195.08.

A number of brokerages recently weighed in on JAZZ. Truist Financial reissued a “buy” rating and issued a $200.00 price target on shares of Jazz Pharmaceuticals in a report on Wednesday, March 20th. Stifel Nicolaus boosted their price objective on Jazz Pharmaceuticals from $225.00 to $230.00 and gave the company a “buy” rating in a research note on Friday, March 15th. Cantor Fitzgerald restated an “overweight” rating and issued a $180.00 price objective on shares of Jazz Pharmaceuticals in a research note on Wednesday, April 10th. UBS Group lowered their price objective on Jazz Pharmaceuticals from $135.00 to $131.00 and set a “neutral” rating on the stock in a research note on Friday, March 1st. Finally, HC Wainwright lowered their price objective on Jazz Pharmaceuticals from $204.00 to $200.00 and set a “buy” rating on the stock in a research note on Thursday, March 14th.

Insider Activity

In related news, CFO Philip L. Johnson acquired 12,000 shares of the company’s stock in a transaction dated Friday, March 1st. The stock was purchased at an average price of $119.65 per share, with a total value of $1,435,800.00. Following the completion of the purchase, the chief financial officer now owns 27,932 shares in the company, valued at approximately $3,342,063.80. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. In other Jazz Pharmaceuticals news, CFO Philip L. Johnson bought 12,000 shares of the firm’s stock in a transaction that occurred on Friday, March 1st. The stock was bought at an average price of $119.65 per share, for a total transaction of $1,435,800.00. Following the completion of the acquisition, the chief financial officer now directly owns 27,932 shares in the company, valued at $3,342,063.80. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Patricia Carr sold 1,936 shares of the company’s stock in a transaction that occurred on Wednesday, March 6th. The shares were sold at an average price of $119.64, for a total value of $231,623.04. Following the transaction, the chief accounting officer now owns 8,364 shares of the company’s stock, valued at approximately $1,000,668.96. The disclosure for this sale can be found here. Insiders own 4.40% of the company’s stock.

Hedge Funds Weigh In On Jazz Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its holdings in shares of Jazz Pharmaceuticals by 0.5% during the third quarter. Vanguard Group Inc. now owns 6,379,053 shares of the specialty pharmaceutical company’s stock valued at $825,705,000 after acquiring an additional 29,960 shares in the last quarter. LSV Asset Management increased its holdings in shares of Jazz Pharmaceuticals by 2.4% during the third quarter. LSV Asset Management now owns 2,372,177 shares of the specialty pharmaceutical company’s stock valued at $307,055,000 after acquiring an additional 55,630 shares in the last quarter. Polaris Capital Management LLC increased its holdings in shares of Jazz Pharmaceuticals by 13.0% during the first quarter. Polaris Capital Management LLC now owns 1,432,660 shares of the specialty pharmaceutical company’s stock valued at $172,521,000 after acquiring an additional 165,200 shares in the last quarter. FMR LLC increased its holdings in shares of Jazz Pharmaceuticals by 8.1% during the third quarter. FMR LLC now owns 1,333,129 shares of the specialty pharmaceutical company’s stock valued at $172,560,000 after acquiring an additional 100,349 shares in the last quarter. Finally, Ameriprise Financial Inc. increased its holdings in shares of Jazz Pharmaceuticals by 4.6% during the third quarter. Ameriprise Financial Inc. now owns 1,299,612 shares of the specialty pharmaceutical company’s stock valued at $168,222,000 after acquiring an additional 57,717 shares in the last quarter. Institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Price Performance

JAZZ opened at $110.75 on Friday. The company has a debt-to-equity ratio of 1.37, a current ratio of 2.24 and a quick ratio of 1.85. The company has a market capitalization of $6.98 billion, a price-to-earnings ratio of 18.10, a P/E/G ratio of 1.51 and a beta of 0.59. The firm’s fifty day moving average price is $117.63 and its two-hundred day moving average price is $121.44. Jazz Pharmaceuticals has a 1 year low of $106.61 and a 1 year high of $146.70.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings data on Wednesday, February 28th. The specialty pharmaceutical company reported $4.40 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $4.44 by ($0.04). The firm had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $1.01 billion. Jazz Pharmaceuticals had a return on equity of 31.27% and a net margin of 10.82%. As a group, analysts anticipate that Jazz Pharmaceuticals will post 16.24 earnings per share for the current fiscal year.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.